Emerging Cancer Vaccines Market to 2017 – Novel, First-In-Class Vaccines in Phase II and Phase III Pipeline to Shape the Future Cancer Vaccines Market

“Emerging Cancer Vaccines Market to 2017 - Novel, First-In-Class Vaccines in Phase II and Phase III Pipeline to Shape the Future Cancer Vaccines Market” provides insights into the global emerging cancer vaccines market and a market forecast until 2017. The report provides an in-depth analysis of the five therapeutic indications for which vaccines are available in the market or which have a promising vaccine in Phase III of their pipeline. In addition, the report also includes various types of cancer vaccine development and vaccine delivery methods along with a case study, advantages and disadvantages for each type, insights into the cancer vaccines R&D pipeline, SWOT profiles of the vaccine companies, and major Mergers and Acquisitions (M&A), deals and co-developments.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

Explore Table of Contents and more of this report @ http://www.reportsnreports.com/reports/135088-emerging-cancer-vaccines-market-to-2017-novel-firstinclass-vaccines-in-phase-ii-and-phase-iii-pipeline-to-shape-the-future-cancer-vaccines-market.html

This analysis shows that the global cancer vaccines market for cervical cancer, prostate cancer, lung cancer, pancreatic cancer and melanoma was valued at $1,657m in 2010. The market is expected to witness a Compound Annual Growth Rate (CAGR) of 21% for the forecast period (2010-2017) and will reach $6.3 billion by 2017. The market will be driven by the launch of promising Phase III molecules in cervical cancer, lung cancer, pancreatic cancer and melanoma. With patent-protection granted to available vaccines, the market will demonstrate significant growth. Strategic consolidations through M&A, deals and co-developments will provide R&D, marketing, sales and regulatory support in the future and help gain a greater market share.

Scope

Reasons to buy

The report will enhance your decision-making capability. It will allow you to -

• Familiarize yourself with the different types of cancer vaccine development and vaccine delivery methods available, with case studies and analysis of advantages and disadvantages for a better understanding of the market.
• Align your product portfolio to the markets with high growth potential.
• Develop market-entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.
• Devise a more tailored country strategy through the understanding of key drivers and barriers of each region’s cancer vaccines market.
• Develop key strategic initiatives by understanding the key focus areas and top selling vaccines of leading companies.
• Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

Request a Sample or Inquire before buying the report 'Emerging Cancer Vaccines Market to 2017 – Novel, First-In-Class Vaccines in Phase II and Phase III Pipeline to Shape the Future Cancer Vaccines Market' @ http://www.reportsnreports.com/reports/135088-emerging-cancer-vaccines-market-to-2017-novel-firstinclass-vaccines-in-phase-ii-and-phase-iii-pipeline-to-shape-the-future-cancer-vaccines-market.html